November 21, 2024
The webinar features a panel discussion of key topics in the field of cancer immunotherapy, including new and emerging methods, recent publications, and future directions. The links between preclinical research, in vivo studies, and biomarkers will be explored, as well as the unique advantages of Crown Bioscience and their service offerings.
Gera Goverse, PhD, Director, Immuno-oncology, Crown Bioscience
Dr. Gera Goverse joined OcellO in 2017 and is Director of Immuno-Oncology at Crown Bioscience Netherlands. Her expertise is in assay development for testing drug candidates targeting the immune cell response leading to the killing of tumors in 3D high content image assays. Dr. Goverse who obtained her PhD in Immunology at the VU Medical Centre Amsterdam and continued her post-doctoral studies at the KU Leuven, applies her obtained knowledge within these complex assays studying different subsets of immune cells and is specialized in the role of the myeloid cell compartment.
Ludovic Bourre, PhD, Vice President, Research & Innovation, Crown Bioscience
Ludovic serves as Executive Director leading the Scientific Engagement department. He has over 15 years of Oncology R&D experience. Prior to joining Crown Bioccience, he worked at Invectys (Paris, France) as head of the pharmacology, leading the preclinical and clinical evaluation of immuno-oncology programs. Ludovic holds a PhD in Pharmacology from Nantes University (France), and served as a postdoctoral researcher in University College London and University College Cork.
Leo Price, PhD, Senior Vice President, In Vitro, Head of Crown Bioscience Netherlands
Leo Price leads Crown Bioscience’s in vitro services in Europe and the US and the Crown Bioscience sites in The Netherlands, Leiden and Utrecht. He joined Crown Bioscience in 2021 from OcellO, following Crown Bioscience’s acquisition of the company. Dr Price was the founder of OcellO, a leading provider of high content screening services, using organoids and other advanced 3D cell culture models, and served as their CEO and CSO for ten years. Prior to founding OcellO, Leo was a Faculty Member and Group Leader at Leiden University for five years and completed three postdoctoral studies with UMC Utrecht, The Netherlands Cancer Institute and Scripps Research Institute. He received his PhD in Cell Physiology from University College London and is currently a guest Associate Professor at the Leiden Academic Centre for Drug Research, Leiden University.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2024-10-31
2023-09-26
landing_page
Integrated Solutions - I/O Targets/Combinations